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Timing of infection and development of
wheeze, eczema, and atopic sensitization
during the first 2 yr of life: The KOALA Birth
Cohort Study
Early-life infections have been implicated in
asthma development both as protective and as
risk factor. Protective effects of repeated viral
infection, defined as episodes of runny nose (1) or
febrile upper respiratory tract infections (2), on
the subsequent development of asthma or allergic
sensitization have been reported. Orofecal patho-
gens have likewise been suggested to protect
against asthma among adults (3, 4). On the other
hand, several upper and lower respiratory tract
pathogens, among which respiratory syncytial
virus (RSV), influenza virus and parainfluenza
virus have been associated with increased risk of
developing wheezing and asthma. Recently, a
strong association was found between rhinovirus
infection and wheezing in infancy (5).
Timing of childhood infection might be essen-
tial for the development of asthma and atopy and
might explain some of the inconsistency found in
literature (1–5). For the protective effect of
microbial load on the developing immune sys-
tem, time windows have been suggested, and in
particular the prenatal period seems to be of
importance (6). On the other hand, during the
same period lung growth takes place and harmful
events in this period might lead to reduced lung
function and eventually to asthma later in life.
We therefore studied if infections of the
mother during pregnancy and of the child in
the first year of life were associated with the
risk of wheeze, eczema, and atopic sensitization
in later infancy (up to age 2 yr) in a large
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To investigate if infections in pregnancy and very early in life present a
risk for wheezing, eczema, or atopic sensitization in later infancy. A
total of 2319 children enrolled before birth in the KOALA Birth Cohort
Study were followed during their first 2 yr of life using repeated ques-
tionnaires. Information was obtained on common colds, fever, and
diarrhea with fever as well as on wheeze and eczema at ages 3 and
7 months and 1 and 2 yr, respectively. Blood samples were collected
from 786 children at age 2 yr for specific immunoglobulin E analyses.
Children with a common cold [adjusted odds ratio (aOR) 2.03 95% CI
1.21–3.41] or fever episode (aOR 1.81 95% CI 1.10–2.96) in the first
3 months of life had a higher risk of new onset wheeze in the second
year of life compared to children who had not. For children with
diarrhea with fever in the first 3 months of life, the aOR for new onset
wheeze in the second year of life was 3.94 (95% CI 1.36–11.40) com-
pared to children without diarrhea. Infections becoming clinically
manifest during the first 3 months of life may be a general marker for a
wheezy phenotype.
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prospective birth cohort study (KOALA study).
Exposure to infection in the first year of life was
studied using age intervals of exposure (i.e., first
3 months of life, 3–7 months-old, and 7–
12 months-old, respectively) to study timing of
exposure-outcome relation in more detail.
Methods
Study population and data collection
The KOALA Birth Cohort Study is a prospective
study targeting the population located in the
middle and southern part of the Netherlands. A
detailed description of the study has been pub-
lished elsewhere (7). In brief, between October
2000 and November 2002 women in their 34th
week of pregnancy, with conventional or alter-
native lifestyle, were enrolled in the study.
Pregnant women with conventional lifestyle
(n = 2343) were recruited from a prospective
study on pregnancy-related pelvic girdle pain and
pregnant women with alternative lifestyle
(n = 491) were recruited through alternative
channels, such as organic food shops, anthropo-
sophic doctors and midwives, or Steiner schools
(7).
Data on prenatal, perinatal, and early life
exposures such as, maternal infections during
pregnancy, infections of the child, housing con-
ditions, and lifestyle factors as well as on atopic
outcomes were collected through repeated ques-
tionnaires (34th week of pregnancy and when the
child was 3, 7, 12, and 24 months-old). From
January 2002 onwards, biosampling has been
performed including the sampling of venous
blood at age 24 months (n = 829) for total and
specific immunoglobulin E (IgE) analyses.
Only children of parents who signed informed
consent and who had completed the first ques-
tionnaire at 34 wk of pregnancy were included in
the study. Children born prematurely (gesta-
tional age < 37 wk) and children with Down
syndrome were excluded from the study. The
KOALA Study was approved by the Ethics
Committee of the University Hospital Maas-
tricht.
Infections
Illness episodes indicating infections of the
mother during the second and third trimester
of pregnancy and of the child during the first
2 yr of life were assessed by questionnaires. In
their 34th week of pregnancy, women were
asked if they had had a common cold, fever
episode (fever > 38C), an influenza-like illness
(fever > 38C for several days, headache,
muscle aches, and/or common cold), or diarrhea
after the 3rd month of pregnancy. After the
child was born, the parents were asked to fill out
questionnaires when the child was 3, 7, 12, and
24 months-old, and each questionnaire included
questions on fever episodes (excluding fever after
vaccination), common cold, and diarrhea (loose
or watery stools ‡ 5 times a day) with fever in
the child. The questionnaires also addressed the
presence of concurrent symptoms in other per-
sons in the household as indication of infectious
etiology.
Wheeze, eczema, and atopic sensitization
The parental questionnaire filled out at each
follow-up included the ISAAC questions on
wheeze and eczema (8). Parents were asked if
the child had had wheezing or whistling since
the previous follow-up moment which could be
answered by yes or no. New onset wheeze was
defined as wheeze reported for the first time in
the respective period in life (i.e. between birth
and 7 months-old, between 7 and 12 months-old,
or between 12 and 24 months-old). New onset
eczema was determined by first positive parental
response to the question if their child had an
intermittent itchy rash in the past months.
Children with only diaper rash, rash around the
eyes and/or scalp scaling were not regarded as
having developed eczema. Blood samples were
analyzed for specific IgE against hens eggs, cows
milk, peanuts, birch, grass pollen, cat, dog, and
house dust mite using radioallergosorbent test
(RAST) as described previously (9, 10). The
detection limit for specific IgE was 0.13 IU/ml.
Atopic sensitization was defined as the presence
of at least one specific IgE level > 0.3 IU/ml at
age 2 yr.
Statistical analysis
Missing data in the questionnaires were treated
as missing in the analyses. Multivariable logistic
regression analysis was used to fit the possible
confounders into the model and to calculate the
adjusted odds ratios (aOR) and corresponding
95% confidence intervals (95% CI). Possible
confounders were identified from literature. Con-
founders included in the model were recruitment
group (conventional; alternative), gender (male;
female), parental history of asthma (no; 1 or both
parents), maternal smoking during pregnancy
(yes; no), number of older siblings (0; > 0),
environmental tobacco smoke (ETS) exposure of
the child [ETS exposure between birth and
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7 months-old (yes; no); ETS exposure between 7
and 12 months-old (yes; no); ETS exposure
between 12 and 24 months-old (yes; no)], dura-
tion of (exclusive and partial) breastfeeding
(never; < 4 months; 4–6 months; > 6 months),
maternal education [low (primary school, prepa-
ratory vocational or lower general secondary
education); middle (vocational, higher general
secondary or pre-university education); high
(higher vocational or academic education)]. In
addition, each model was adjusted for illness
episodes indicating infections reported in the age
interval in which the outcome was measured.
Results
Of the 2834 infants in the cohort at birth, 96
children were excluded because they had been
born prematurely and another four children
because of Down syndrome. After 2 yr of fol-
low-up, 415 children had incomplete follow-up
data, leaving 2319 (82%) children for analysis, 786
of whom had also provided a blood sample.
As Table 1 illustrates, the distribution of char-
acteristics in children with complete follow-up at
age 2 yr is comparable to the distribution in the
whole cohort at birth. Recruitment period for
blood sampling coincidedwith the period inwhich
alternative participants were recruited and as a
result the subgroup that provided blood samples
included proportionally more families with alter-
native lifestyle. This is also reflected in the
prevalence of certain characteristics associated
with alternative lifestyle such as longer duration of
breastfeeding, less ETS exposure, and higher
maternal education level in this subgroup.
Eczema was present in 32.5% (754/2319) of the
children in the first 2 yr of life; 17.2% of the
children had eczema already during the first
6 months of life, 6.3% of the children had new
onset eczema between 7 and 12 months of age,
and 13.0% in the second year of life. For new
onset wheeze between birth and age 7 months,
between 7 and 12 months, and between 12 and
24 months, the proportions were 14.1%, 11.9%,
and 7.1%, respectively. At the age of 2 yr, 27.4%
(215/786) of the children were sensitized against
one or more common allergens.
Most children (71.4%) had already had a cold
in their first 3 months of life (Table 1). Fever
episodes were less common in the first 3 months of
life (15.1%). Only 2.0% of the children had
diarrhea with fever during their first 3 months of
life, in the second year of life this was almost 15%.
Illness episodes indicative for infections in the
mother when pregnant were not associated with
eczema, wheeze or atopic sensitization in the
child (Tables 2–4). Common cold, fever episodes,
and diarrhea with fever in the child were asso-
ciated with new onset wheeze in the same time
period as the infection-like symptoms occurred
(Table 2). Infection-like symptoms experienced
in the first 3 months of life remained a risk for
new onset wheeze in later infancy, also when
adjusted for infection-like symptoms occurring in
the period in which new onset wheeze was
measured (Table 2). Children with a common









Male 1388 (50.9) 1186 (51.2) 409 (52.0)
Female 1341 (49.0) 1132 (48.8) 377 (48.0)
Recruitment group
Conventional 2259 (82.6) 1876 (80.9) 557 (70.9)
Alternative 475 (17.4) 443 (19.1) 229 (29.1)
Parental asthma
No 2121 (82.5) 1881 (82.7) 657 (84.1)
1 or both parents 449 (17.5) 394 (17.3) 124 (15.9)
Siblings
No older siblings 2173 (83.0) 1913 (83.1) 652 (83.0)
Older siblings 445 (17.0) 338 (16.9) 134 (17.0)
Breastfeeding (in months)
Never – 327 (14.6) 101 (13.1)
< 4 – 701 (31.3) 203 (26.3)
4–6 – 388 (17.3) 148 (19.2)
> 6 – 826 (36.8) 319 (41.3)
Maternal smoking during pregnancy
No 2535 (92.7) 2176 (93.8) 748 (95.2)
Yes 199 (7.3) 143 (6.2) 38 (4.8)
ETS exposure child
ETS at age 3 or 7 months – 1345 (58.6) 421 (53.8)
ETS at age 12 months – 1097 (47.3) 337 (42.9)
ETS at age 24 months – 1256 (54.2) 374 (47.6)
Maternal education
Low 274 (10.2) 212 (9.2) 59 (7.6)
Middle 1128 (41.8) 945 (41.2) 291 (37.3)
High 1297 (48.1) 1135 (49.5) 430 (55.1)
Common cold
Pregnancy – 1480 (63.9) 544 (69.2)
Childs age 0–3 months – 1599 (71.4) 541 (70.3)
Childs age 3–7 months – 1963 (85.1) 667 (85.0)
Childs age 7–12 months – 2030 (88.1) 692 (88.4)
Fever
Pregnancy – 213 (9.2) 86 (11.0)
Childs age 0–3 months – 339 (15.1) 112 (14.5)
Childs age 3–7 months – 1237 (53.5) 428 (54.7)
Childs age 7–12 months – 1578 (68.5) 536 (68.9)
Diarrhea
Pregnancy – 514 (22.2) 165 (21.0)
Childs age 0–3 months – 46 (2.0) 11 (1.4)
Childs age 3–7 months – 203 (8.8) 46 (5.9)
Childs age 7–12 months – 263 (11.5) 92 (11.8)
*Complete follow-up; questionnaires filled out at 7, 12, and 24 months.
All categories combined (less than 1 h/wk, less than 1 h/day, between 1 and
4 h/day, more than 4 h/day).
ETS, environmental tobacco smoke.
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Table 2. Risk for new onset wheeze in three periods during the first 2 yr of life in relation to timing of infection
New onset wheeze
0–7 months 7–12 months 12–24 months
n/N aOR (95% CI)* n/N aOR (95% CI)* n/N aOR (95% CI)*
Pregnancy
Common cold 307/2190 1.30 (1.00–1.71) 224/1886 1.12 (0.83–1.53) 109/1571 0.98 (0.65–1.48)
Fever (> 38C) 307/2189 0.77 (0.48–1.21) 224/1886 0.91 (0.56–1.47) 109/1568 0.88 (0.43–1.80)
Influenza-like illness 306/2188 1.17 (0.79–1.74) 223/1885 1.02 (0.64–1.63) 109/1569 0.80 (0.39–1.64)
Diarrhea 306/2187 1.11 (0.83–1.49) 224/1884 0.98 (0.69–1.38) 109/1569 0.72 (0.42–1.22)
Early life
0–3 months
Common cold 302/2137 1.56 (1.15–2.12) 217/1823 1.46 (1.03–2.06) 105/1517 2.03 (1.21–3.41)
Fever 299/2147 1.52 (1.11–2.08) 217/1836 1.22 (0.82–1.81) 106/1530 1.81 (1.10–2.96)
Diarrhea with fever 302/2146 1.81 (0.89–3.70) 217/1832 1.25 (0.45–3.44) 107/1525 3.94 (1.36–11.40)
3–7 months
Common cold 309/2205 1.53 (1.04–2.25) 221/1877 1.55 (0.97–2.49) 108/1563 1.74 (0.89–3.43)
Fever 309/2211 2.10 (1.61–2.73) 223/1882 1.36 (1.01–1.83) 108/1568 1.00 (0.67–1.50)
Diarrhea with fever 308/2205 1.56 (1.07–2.27) 221/1878 1.82 (1.16–2.84) 109/1564 1.35 (0.68–2.68)
7–12 months
Common cold 229/1908 2.42 (1.38–4.25) 109/1557 1.62 (0.77–3.43)
Fever 227/1912 3.75 (2.51–5.62) 109/1564 1.34 (0.85–2.11)
Diarrhea with fever 225/1899 2.56 (1.79–3.67) 108/1553 1.86 (1.06–3.24)
*Adjusted for recruitment group (conventional/alternative), gender (male/female), parental history of asthma (no/1 or both parents), maternal smoking during
pregnancy (yes/no), environmental tobacco smoke (ETS) exposure of child for the respective age interval (i.e. (no/yes at age 3 months) (no/yes at age 7 months) (no/
yes at age 12 months) or (no/yes at age 24 months), number of older siblings (0/> 0), duration of breastfeeding (never/< 4 months/4–6 months/> 6 months),
maternal education (low/middle/high) and common cold, fever and diarrhea in the same age-interval as new onset wheeze.
aOR, adjusted odds ratio.
Table 3. Risk for new onset eczema in three periods during the first 2 yr of life in relation to timing of first infection
New onset eczema
0–7 months 7–12 months 12–24 months
n/N aOR (95% CI)* n/N aOR (95% CI)* n/N aOR (95% CI)*
Pregnancy
Common cold 375/2198 0.93 (0.74–1.18) 112/1825 1.23 (0.80–1.87) 214/1610 0.97 (0.72–1.32)
Fever (> 38C) 376/2197 0.94 (0.64–1.40) 112/1824 0.77 (0.38–1.58) 214/1608 0.84 (0.50–1.42)
Influenza-like illness 374/2196 0.83 (0.56–1.23) 111/1824 0.98 (0.52–1.84) 214/1610 0.81 (0.49–1.35)
Diarrhea 376/2195 1.06 (0.81–1.39) 111/1821 0.69 (0.41–1.16) 213/1609 1.12 (0.79–1.58)
Early life
0–3 months
Common cold 370/2145 1.22 (0.94–1.58) 107/1760 1.16 (0.74–1.82) 207/1554 1.18 (0.84–1.64)
Fever 370/2155 1.10 (0.81–1.51) 106/1770 1.46 (0.89–2.40) 208/1566 0.89 (0.58–1.37)
Diarrhea with fever 369/2154 0.61 (0.23–1.58) 107/1770 1.40 (0.41–4.77) 208/1563 0.75 (0.22–2.52)
3–7 months
Common cold 380/2213 1.15 (0.83–1.59) 111/1820 0.89 (0.52–1.50) 214/1607 1.42 (0.90–2.24)
Fever 381/2219 1.11 (0.89–1.39) 112/1824 1.00 (0.67–1.49) 214/1610 1.32 (0.98–1.79)
Diarrhea with fever 381/2213 1.03 (0.70–1.51) 109/1819 1.12 (0.58–2.19) 214/1607 1.09 (0.65–1.84)
7–12 months
Common cold 116/1846 1.68 (0.83–3.37) 213/1600 1.42 (0.84–2.39)
Fever 114/1847 1.09 (0.72–1.66) 214/1605 1.39 (0.99–1.94)
Diarrhea with fever 114/1840 1.77 (1.08–2.91) 212/1597 1.22 (0.78–1.90)
*Adjusted for recruitment group (conventional/alternative), gender (male/female), parental history of asthma (no/1 or both parents), maternal smoking during
pregnancy (yes/no), environmental tobacco smoke (ETS) exposure of the child for the respective age interval (i.e. (no/yes at age 3 months) (no/yes at age 7 months)
(no/yes at age 12 months) or (no/yes at age 24 months), number of older siblings (0/> 0), duration of breastfeeding (never/< 4 months/4–6 months/> 6 months),
maternal education (low/middle/high) and common cold, fever and diarrhea in the same age-interval as new onset eczema.
aOR, adjusted odds ratio.
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cold or fever episode in the first 3 months of life
had an about two times higher risk of new onset
wheeze in the second year of life compared to
children who had not had a common cold (aOR
2.03 95% CI 1.21–3.41) or fever episode (aOR
1.81 95% CI 1.10–2.96) in the first 3 months of
life. For children who had had diarrhea with
fever in their first 3 months of life, the risk for
new onset wheeze in the second year of life was
four times that of children without diarrhea
(aOR 3.94 95% CI 1.36–11.40).
Infection-like symptoms after the first
3 months of life were also associated with new
onset wheeze in later infancy; infection-like symp-
toms between 3 and 7 months of life were asso-
ciated with new onset wheeze when the children
were 7–12 months-old, but not thereafter.
For diarrhea with fever between 7 and
12 months of age, the risk for new onset wheeze
in the second year of life was increased (aOR 1.86
95% CI 1.06–3.24), but for common cold and
fever episodes experienced between 7 and
12 months-old no association with wheeze in
the second year of life was seen. Eczema was not
associated with childhood infections except for a
modestly increased risk for new onset eczema in
the second year of life in children with an episode
of fever between 3 and 7 months-old or between
7 and 12 months-old (Table 3). Atopic sensitiza-
tion at age two was not associated with any of
the infection-like symptoms regardless of the age
period in which they occurred (Table 4).
Discussion
In this prospective birth cohort study, an
association was found between infection-like
symptoms during the first 3 months of life and
new-onset wheeze in later infancy. In particular,
infants who had diarrhea with fever in the first
3 months of life had a substantially higher risk of
new onset wheeze in the second year of life. No
associations were seen between any of the infec-
tion-like symptoms experienced in the first
3 months of life and new onset eczema or allergic
sensitization in the first 2 yr of life.
Infections in early life have been implicated in
asthma development both as protective factor
and as risk factor. Protective effects of (indices
of) infection in early life on atopy and asthma
have been found in school-aged children (1).
Lower respiratory tract infections were found to
be associated with increased risk of wheezing (1,
11), especially so in younger children (12). In the
present study, we also found that infection-like
symptoms were a risk factor for wheeze, but not
for atopic sensitization or eczema. Fever in the
first 3 months of life, as a general marker of
infection, was associated with an almost two
times higher risk of new onset wheeze in the
second year of life. Others have found that febrile
episodes between 7 and 12 months of age
decreased the risk of the subsequent development
of allergic sensitization or asthma with allergic
sensitization at age 6 and 7 yr (2, 13). Upper
respiratory tract infections in infancy, defined as
episodes of runny nose, were also found to
protect against asthma in 7-yr-old children (1).
By contrast, very recently rhinovirus infection
has been reported to be strongly associated with
wheeze in young children (5). In line with the
findings from the present study, rhinovirus
infections have been found to increase the risk
of wheeze at the age of 3 yr (5) and at 5 yr (14).
Both previous studies (5, 14) investigated rhino-
virus infections in the first year of life, whereas in
the present study we found that common colds,
most likely caused by rhinovirus infection, expe-
rienced as early as the first 3 months of life
presented the greatest risk for new onset wheez-
ing in the second year of life. For fever, as non-
specific indicator of infection, and diarrhea with
fever, as presumed indicator of gastrointestinal
infections like rota- or norovirus, we found
similar associations with wheeze when experi-
enced in the first 3 months of life as we did with
Table 4. Risk for allergic sensitization at age 2 yr in relation to timing of
infection
Allergic sensitization
n/N aOR (95% CI)*
Pregnancy
Common cold 210/775 1.21 (0.84–1.74)
Fever (> 38C) 209/774 1.01 (0.60–1.68)
Diarrhea 210/775 0.94 (0.63–1.41)
Influenza-like illness 208/773 1.08 (0.66–1.76)
Early life
0–3 months
Common cold 207/759 0.79 (0.55–1.12)
Fever 207/763 1.19 (0.75–1.87)
Diarrhea with fever 208/762 0.32 (0.04–2.59)
3–7 months
Common cold 210/774 0.74 (0.48–1.15)
Fever 210/772 1.20 (0.86–1.67)
Diarrhea with fever 209/772 0.99 (0.49–2.00)
7–12 months
Common cold 209/772 0.92 (0.55–1.52)
Fever 208/767 0.95 (0.67–1.36)
Diarrhea with fever 207/767 1.12 (0.68–1.83)
*Adjusted for recruitment group (conventional/alternative), gender (male/fe-
male), parental history of asthma (no/1 or both parents), maternal smoking
during pregnancy (yes/no), environmental tobacco smoke (ETS) exposure of the
at age 24 months, number of older siblings (0/> 0), and duration of breast-
feeding (never/< 4 months/4–6 months/> 6 months), maternal education
(low/middle/high).
aOR, adjusted odds ratio.
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common colds. These results suggest that infec-
tions that become clinically manifest very early in
life may be a general marker for an infant wheezy
phenotype, however, not necessarily resulting in
asthma in later life. Immature innate immunity at
birth, defined as the inability to mount appro-
priate c-interferon (IFN-c) responses to viral
infection has been found to be associated with a
higher risk of symptomatic viral infection in
infancy (15) and may be especially important for
severity of disease (15, 16). Moreover, in the
Tucson Study, IFN-c production at age
9 months was inversely associated with wheeze
occurring before age 6 yr (17). Alternative mech-
anisms might involve prolonged non-specific
airway hyper-responsiveness, as seen in atopics,
resulting from an increased rate of symptomatic
colds (18) or deficient interferon-b response,
impaired apoptosis, and increased virus replica-
tion as demonstrated in bronchial epithelial cells
from asthmatic subjects (19). We were surprised
to find that diarrhea with fever, a symptom of
gastro-intestinal infection, was the infection-like
symptom most strongly associated with subse-
quent new onset wheeze. We observed that when
for children diarrhea with fever was reported, in
most cases (> 50%) for another house-hold
member the same symptoms were reported in
the same time-period, underlining the infectious
nature of the symptoms (data not presented).
The most common causes of gastroenteritis in
children of this age are rotavirus and norovirus
infection, and recently it was reported that
rotavirus may also spread beyond the intestine
to other sites, among which the lungs (20). In
humans, shedding of this virus in the respiratory
tract and pulmonary complications has been
described (21–23). Although this finding might
reflect a more general susceptibility to clinical
infection coinciding with predisposition to
wheeze, in analogy to the mechanism suggested
for respiratory infections, it is tempting to
speculate that rotavirus infection might also have
impact on lung development in susceptible indi-
viduals. To our knowledge, no other studies have
investigated gastro-intestinal infections and ato-
pic outcomes in infancy, although studies have
found that salmonellosis in infancy is associated
with lower risk of asthma and atopy in later
childhood or adolescence (24), and gastrointesti-
nal infections have been associated with lower
risk of asthma and allergies in young male adults
(4). Although we found no protective effect of
symptoms of gastro-intestinal infection in chil-
dren up to age 2 yr-old, we cannot exclude the
possibility that such an effect may become
apparent when the children grow older.
Strengths of this study are its prospective,
population based, design, and the large numbers
of participants included, providing the opportu-
nity to study new onset of symptoms at several
ages in infancy. Because of the high follow-up
rate after 2 yr, the study population during
follow-up was comparable to the study popula-
tion at time of inclusion for most population
characteristics. The children providing blood
samples for specific IgE analyses differed in some
respects from the study population at time of
inclusion because of the later start of blood
sampling in the cohort. However, we do not
expect our data to be systematically biased by
differential response or differential loss to follow-
up. A limitation of the present study is that we
relied on parentally reported information on
wheeze, eczema, and infections. Wheeze and
eczema were measured using the ISAAC ques-
tions, which only have been validated for older
children. Information bias is inherent to the use
of questionnaires and we cannot exclude the
possibility of information bias in the present
study. When parents differ in the propensity to
report infections and if those parents who tend to
underreport infections also underreport atopic
outcomes, spurious associations between infec-
tions and atopic manifestations may occur. A
number of observations contradict this. First,
this would be strongest for related symptoms
such as respiratory infections and wheeze but this
does not explain associations with dissimilar
symptoms, such as diarrhea and wheeze. Second,
if this was the case also eczema would have been
overreported, but eczema was not associated
with any of the infections studied. Also infection-
like symptoms were assessed by questionnaire. In
very young infants, a blocked nose is common
and not necessarily of infectious nature (i.e.
common cold). This may explain the high prev-
alence of common cold symptoms in the age
group 0–3 month-olds in our study. However,
common colds are most prevalent in the first year
of life (mean annual number of episodes reported
in a German birth Cohort study was 3.1 (s.d. 2.1)
(25), and in an Australian study one-third of the
infants was reported to have had an upper
respiratory tract infection already by age
1 month-old (26). Several factors may have
influenced the prevalence of infectious symptoms
at the different ages, such as breastfeeding which
has previously been found to protect against
rotavirus seropositivity in the KOALA cohort
(27). For the present study, we also found that
breastfeeding protected against infectious symp-
toms whereas daycare attendance conveyed a
risk. In the multivariable analyses, we adjusted
Mommers et al.
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for these and other (potential) confounders and
we therefore think it unlikely that these factors
have largely influenced our results.
In conclusion, infection-like symptoms during
the first 3 months of life are a risk factor for
wheeze in later infancy but were not associated
with eczema or atopic sensitization. As this was
also found for infection-like symptoms other
than those suggestive for respiratory tract infec-
tions, this suggests that infections that become
clinically manifest during the first 3-months of
life may be a general marker for a wheezy
phenotype but are not necessarily causally
related to the development of asthma later in
life. On the other hand, the finding that diarrhea
with fever was strongly associated with wheeze
warrants further study concerning the associa-
tion between enteric viruses and infant wheeze.
References
1. Illi S, von Mutius E, Lau S, et al. Early childhood
infectious diseases and the development of asthma up to
school age: a birth cohort study. BMJ 2001: 322: 390–5.
2. Williams LK, Peterson EL, Ownby DR, Johnson CC.
The relationship between early fever and allergic sensi-
tization at age 6 to 7 years. J Allergy Clin Immunol
2004: 113: 291–6.
3. Matricardi PM, Rosmini F, Panetta V, Ferrigno L,
Bonini S. Hay fever and asthma in relation to markers
of infection in the United States. J Allergy Clin
Immunol 2002: 110: 381–7.
4. Matricardi PM, Rosmini F, Riondino S, et al.
Exposure to foodborne and orofecal microbes versus
airborne viruses in relation to atopy and allergic asth-
ma: epidemiological study. BMJ 2000: 320: 412–7.
5. Lemanske RF Jr, Jackson DJ, Gangnon RE, et al.
Rhinovirus illnesses during infancy predict subsequent
childhood wheezing. J Allergy Clin Immunol 2005: 116:
571–7.
6. Ege MJ, Bieli C, Frei R, et al. Prenatal farm exposure
is related to the expression of receptors of the innate
immunity and to atopic sensitization in school-age
children. J Allergy Clin Immunol 2006: 117: 817–23.
7. Kummeling I, Thijs C, Penders J, et al. Etiology
of atopy in infancy: the KOALA Birth cohort Study.
Pediatr Allergy Immunol 2005: 16: 679–84.
8. Asher MI, Keil U, Anderson HR, et al. International
Study of Asthma and Allergies in Childhood (ISAAC):
rationale and methods. Eur Respir J 1995: 8: 483–91.
9. Aalberse RC, Koshte V, Clemens JG. Immunoglob-
ulin E antibodies that crossreact with vegetable foods,
pollen, and Hymenoptera venom. J Allergy Clin
Immunol 1981: 68: 356–64.
10. Schuurman J, Perdok GJ, Lourens TE, Parren PW,
Chapman MD, Aalberse RC. Production of a mouse/
human chimeric IgE monoclonal antibody to the house
dust mite allergen Der p 2 and its use for the absolute
quantification of allergen-specific IgE. J Allergy Clin
Immunol 1997: 99: 545–50.
11. Nafstad P, Brunekreef B, Skrondal A, Nystad W.
Early respiratory infections, asthma, and allergy:
10-year follow-up of the Oslo Birth Cohort. Pediatrics
2005: 116: e255–62.
12. Gern JE, Rosenthal LA, Sorkness RL, Lemanske
RF Jr. Effects of viral respiratory infections on lung
development and childhood asthma. J Allergy Clin
Immunol 2005: 115: 668–74.
13. Williams LK, Peterson EL, Pladevall M, Tunceli
K, Ownby DR, Johnson CC. Timing and intensity of
early fevers and the development of allergies and asth-
ma. J Allergy Clin Immunol 2005: 116: 102–8.
14. Kusel MM, de Klerk NH, Kebadze T, et al. Early-life
respiratory viral infections, atopic sensitization, and
risk of subsequent development of persistent asthma.
J Allergy Clin Immunol 2007: 119: 1105–10.
15. Copenhaver CC, Gern JE, Li Z, et al. Cytokine
response patterns, exposure to viruses, and respiratory
infections in the first year of life. Am J Respir Crit Care
Med 2004: 170: 175–80.
16. Guerra S, Lohman IC, Halonen M, Martinez FD,
Wright AL. Reduced interferon gamma production
and soluble CD14 levels in early life predict recurrent
wheezing by 1 year of age. Am J Respir Crit Care Med
2004: 169: 70–6.
17. Stern DA, Guerra S, Halonen M, Wright AL,
Martinez FD. Low IFN-gamma production in the first
year of life as a predictor of wheeze during childhood. J
Allergy Clin Immunol 2007: 120: 835–41.
18. Xepapadaki P, Papadopoulos NG, Bossios A,
Manoussakis E, Manousakas T, Saxoni-Papageor-
giou P. Duration of postviral airway hyperresponsive-
ness in children with asthma: effect of atopy. J Allergy
Clin Immunol 2005: 116: 299–304.
19. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic
bronchial epithelial cells have a deficient innate immune
response to infection with rhinovirus. J Exp Med 2005:
201: 937–47.
20. Blutt SE, Conner ME. Rotavirus: to the gut and
beyond! Curr Opin Gastroenterol 2007;23:39–43.
21. Azevedo MS, Yuan L, Jeong KI, et al. Viremia and
nasal and rectal shedding of rotavirus in gnotobiotic
pigs inoculated with Wa human rotavirus. J Virol 2005:
79: 5428–36.
22. Wennergren G, Hansson S, Engstrom I, et al.
Characteristics and prognosis of hospital-treated
obstructive bronchitis in children aged less than two
years. Acta Paediatr 1992: 81: 40–5.
23. Zheng BJ, Chang RX, Ma GZ, et al. Rotavirus
infection of the oropharynx and respiratory tract in
young children. J Med Virol 1991: 34: 29–37.
24. Pelosi U, Porcedda G, Tiddia F, et al. The inverse
association of salmonellosis in infancy with allergic
rhinoconjunctivitis and asthma at school-age: a longi-
tudinal study. Allergy 2005: 60: 626–30.
25. Gruber C, Keil T, Kulig M, et al. History of respira-
tory infections in the first 12 yr among children from a
birth cohort. Pediatr Allergy Immunol 2008: 19: 505–12.
26. Kemp A, Ponsonby A-L, Dwyer T, et al. The interac-
tion between early life upper respiratory tract infection
and birth during the pollen season on rye-sensitized hay
fever and ryegrass sensitization – a birth cohort study.
Pediatr Allergy Immunol 2009: 20: 536–44.
27. Reimerink J, Stelma F, Rockx B, et al. Early-life
rotavirus and norovirus infections in relation to devel-
opment of atopic manifestation in infants. Clin Exp
Allergy 2009: 39: 254–60.
Infections and atopic manifestations
989
